Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

被引:63
作者
Elena, Chiara
Passamonti, Francesco [1 ]
Rumi, Elisa
Malcovati, Luca
Arcaini, Luca
Boveri, Emanuela [2 ]
Merli, Michele
Pietra, Daniela
Pascutto, Cristiana
Lazzarino, Mario
机构
[1] Univ Pavia, Sch Med, Dept Hematol Oncol, Div Hematol, Pavia, Italy
[2] Fdn IRCCS Policlin San Matteo, Dept Human Pathol, Pavia, Italy
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2011年 / 96卷 / 01期
关键词
myelofibrosis; leukemia; prognosis; transfusion; JAK2; MPL; INTERNATIONAL WORKING GROUP; WORLD-HEALTH-ORGANIZATION; MYELOPROLIFERATIVE DISORDERS; ESSENTIAL THROMBOCYTHEMIA; MYELOID METAPLASIA; POLYCYTHEMIA-VERA; DIAGNOSIS; MUTATION; JAK2; RATIONALE;
D O I
10.3324/haematol.2010.031831
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk stratification in primary myelofibrosis is currently based on two international prognostic scoring systems, neither of which takes into consideration red blood cell transfusion-dependency. In 288 consecutive patients with primary myelofibrosis, red blood cell transfusion-dependency at diagnosis affects survival independently of the International Prognostic Scoring System (P<0.001). To evaluate the dynamic impact on survival of red blood cell transfusion-dependency, we performed a Cox's regression analysis with transfusion status as time-dependent covariate in 220 regularly followed patients with primary myelofibrosis. Patients who begin red blood cell transfusions anytime (n=80, 36%) have a significantly worse survival compared to those who continue follow up without transfusions (HR: 7.8, 95%CI: 5.1-11.9; P<0.001). Adjusting for Dynamic International Prognostic Scoring System in a multivariate analysis, red blood cell transfusion-dependency retained an independent prognostic impact on survival. This study suggests that red blood cell transfusion-dependency should be considered to improve risk stratification of primary myelofibrosis during follow up.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 24 条
[1]   Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment [J].
Barosi, G. ;
Mesa, R. A. ;
Thiele, J. ;
Cervantes, F. ;
Campbell, P. J. ;
Verstovsek, S. ;
Dupriez, B. ;
Levine, R. L. ;
Passamonti, F. ;
Gotlib, J. ;
Reilly, J. T. ;
Vannucchi, A. M. ;
Hanson, C. A. ;
Solberg, L. A. ;
Orazi, A. ;
Tefferi, A. .
LEUKEMIA, 2008, 22 (02) :437-438
[2]   MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort [J].
Beer, Philip A. ;
Campbell, Peter J. ;
Scott, Linda M. ;
Bench, Anthony J. ;
Erber, Wendy N. ;
Bareford, David ;
Wilkins, Bridget S. ;
Reilly, John T. ;
Hasselbalch, Hans C. ;
Bowman, Richard ;
Wheatley, Keith ;
Buck, Georgina ;
Harrison, Claire N. ;
Green, Anthony R. .
BLOOD, 2008, 112 (01) :141-149
[3]   V617F mutation in JAK2 is associated idiopathic myelofibrosis [J].
Campbell, PJ ;
Griesshammer, M ;
Döhner, K ;
Döhner, H ;
Kusec, R ;
Hasselbalch, HC ;
Larsen, TS ;
Pallisgaard, N ;
Giraudier, S ;
Le Bousse-Kerdilès, MC ;
Desterke, C ;
Guerton, B ;
Dupriez, B ;
Bordessoule, D ;
Fenaux, P ;
Kiladjian, JJ ;
Viallard, JF ;
Brière, J ;
Harrison, CN ;
Green, AR ;
Reilly, JT .
BLOOD, 2006, 107 (05) :2098-2100
[4]   Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders [J].
Cervantes, F. ;
Passamonti, F. ;
Barosi, G. .
LEUKEMIA, 2008, 22 (05) :905-914
[5]   Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia:: results in 20 patients and review of the literature [J].
Cervantes, F ;
Alvarez-Larrán, A ;
Hernández-Boluda, JC ;
Sureda, A ;
Torrebadell, M ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (04) :399-403
[6]   New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [J].
Cervantes, Francisco ;
Dupriez, Brigitte ;
Pereira, Arturo ;
Passamonti, Francesco ;
Reilly, John T. ;
Morra, Enrica ;
Vannucchi, Alessandro M. ;
Mesa, Ruben A. ;
Demory, Jean-Loup ;
Barosi, Giovanni ;
Rumi, Elisa ;
Tefferi, Ayalew .
BLOOD, 2009, 113 (13) :2895-2901
[7]  
GALE RP, 2010, LEUK RES 0805
[8]   Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation [J].
Guglielmelli, Paola ;
Pancrazzi, Alessandro ;
Bergamaschi, Gaetano ;
Rosti, Vittorio ;
Villani, Laura ;
Antonioli, Elisabetta ;
Bosi, Alberto ;
Barosi, Giovanni ;
Vannucchi, Alessandro M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (03) :244-247
[9]   A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[10]   Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation [J].
Kroeger, Nicolaus ;
Holler, Ernst ;
Kobbe, Guido ;
Bornhaeuser, Martin ;
Schwerdtfeger, Rainer ;
Baurmann, Herrad ;
Nagler, Arnon ;
Bethge, Wolfgang ;
Stelljes, Matthias ;
Uharek, Lutz ;
Wandt, Hannes ;
Burchert, Andreas ;
Corradini, Paolo ;
Schubert, Joerg ;
Kaufmann, Martin ;
Dreger, Peter ;
Wulf, Gerald G. ;
Einsele, Hermann ;
Zabelina, Tatjana ;
Kvasnicka, Hans Michael ;
Thiele, Juergen ;
Brand, Ronald ;
Zander, Axel R. ;
Niederwieser, Dietger ;
de Witte, Theo M. .
BLOOD, 2009, 114 (26) :5264-5270